Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Recurrent or metastatic head and neck squamous cell carcinoma, drawn from the whole corpus: 45 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients still die within two years.
No test yet identifies the minority who gain years from immunotherapy.
Salvage surgery and re-irradiation carry high complication rates.
Access to pembrolizumab and cetuximab in the countries with the most cases.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Median OS 10 vs 5 months, HR 0.
A milestone in how this cancer is treated.
1-year OS 43.
A milestone in how this cancer is treated.
TPEx did not improve overall survival over EXTREME, but gave similar survival with a shorter schedule and less toxicity.